RLS Radiopharmacies
Website to be confirmed.
About RLS Radiopharmacies
RLS Radiopharmacies is a CDMO / CMO company; the kind of vendor BD teams should have a 15-minute conversation with at SNMMI.
Longer summary placeholder. Replace once Bracken finalizes the exhibitor profile copy.
What we're seeing
- Endpoints News · 2026-12-17Rls Radiopharmacies signs supply agreement to support late-stage trialsThe work builds on more than a decade of radiochemistry collaboration.
- Reuters Health · 2026-11-22Rls Radiopharmacies appoints new Chief Medical Officer ahead of pivotal trialCoverage notes the company's growing footprint in the radioligand therapy space.
- BioPharma Reporter · 2026-02-15Rls Radiopharmacies announces Phase II readout for lead theranostic candidateCoverage notes the company's growing footprint in the radioligand therapy space.
- FierceBiotech · 2026-01-24Rls Radiopharmacies expands cyclotron capacity to meet Lu-177 demandThe announcement comes amid tightening Mo-99 and Lu-177 supply.
- STAT News · 2026-04-05Rls Radiopharmacies partners with academic center on Actinium-225 programDetails remain limited but analysts read the move as a positioning play ahead of pivotal data.
Mocked while we wire the Exa integration. Headlines are illustrative.
What we expect to see at the booth
Booth talking points, demos, and announcements to watch for. Bracken analyst note coming.
A short Bracken POV will go here, drawing on our experience across this part of the radiopharma value chain. Specific commentary to be filled in by the team.
Editorial shown for exhibitors in Bracken's wheelhouse: radiopharma developers, isotope supply, CDMO/CMO, cyclotron, and imaging equipment.
Companies you may also want to visit.
AtomVie Global Radiopharma Inc.
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on AtomVie Global Radiopharma Inc..
View profile →CDL Nuclear Technologies
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on CDL Nuclear Technologies.
View profile →Jubilant Radiopharma
Profile under construction. Check back closer to SNMMI 2026 for Bracken's read on Jubilant Radiopharma.
View profile →